pubmed.ncbi.nlm.nih.gov

Impact of the Cannabinoid System in Alzheimer's Disease - PubMed

Review

Impact of the Cannabinoid System in Alzheimer's Disease

Shuangtao Li et al. Curr Neuropharmacol. 2023.

Abstract

Cannabinoids are compounds isolated from cannabis and are also widely present in both nervous and immune systems of animals. In recent years, with in-depth research on cannabinoids, their clinical medicinal value has been evaluated, and many exciting achievements have been continuously accumulating, especially in the field of neurodegenerative disease. Alzheimer's disease is the most common type of neurodegenerative disease that causes dementia and has become a global health problem that seriously impacts human health today. In this review, we discuss the therapeutic potential of cannabinoids for the treatment of Alzheimer's disease. How cannabinoids act on different endocannabinoid receptor subtypes to regulate Alzheimer's disease and the roles of the endocannabinoid system in Alzheimer's disease are outlined, and the underlying mechanisms are discussed. Finally, we summarize the most relevant opportunities of cannabinoid pharmacology related to Alzheimer's disease and discuss the potential usefulness of cannabinoids in the clinical treatment of Alzheimer's disease.

Keywords: Alzheimer's disease; CB1 receptor; CB2 receptor; Cannabinoids; endocannabinoid; neurodegenerative diseases.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest, financial or otherwise.

Figures

**Fig. (1)**
CB2R-mediated neuroprotection.

Cited by

A Comprehensive Exploration of the Multifaceted Neuroprotective Role of Cannabinoids in Alzheimer's Disease across a Decade of Research.
Tyrakis P, Agridi C, Kourti M. Tyrakis P, et al. Int J Mol Sci. 2024 Aug 7;25(16):8630. doi: 10.3390/ijms25168630. Int J Mol Sci. 2024. PMID: 39201317 Free PMC article. Review.
Unveiling the Potential of Phytocannabinoids: Exploring Marijuana's Lesser-Known Constituents for Neurological Disorders.
Basavarajappa BS, Subbanna S. Basavarajappa BS, et al. Biomolecules. 2024 Oct 13;14(10):1296. doi: 10.3390/biom14101296. Biomolecules. 2024. PMID: 39456229 Free PMC article. Review.
Exploring Cannabinoids with Enhanced Binding Affinity for Targeting the Expanded Endocannabinoid System: A Promising Therapeutic Strategy for Alzheimer's Disease Treatment.
Stanciu GD, Ababei DC, Solcan C, Uritu CM, Craciun VC, Pricope CV, Szilagyi A, Tamba BI. Stanciu GD, et al. Pharmaceuticals (Basel). 2024 Apr 19;17(4):530. doi: 10.3390/ph17040530. Pharmaceuticals (Basel). 2024. PMID: 38675490 Free PMC article.

References

1. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443(7113):787–795. doi: 10.1038/nature05292. - DOI - PubMed
1. Selkoe D.J. Cell biology of protein misfolding: the examples of Alzheimer’s and Parkinson’s diseases. Nat. Cell Biol. 2004;6(11):1054–1061. doi: 10.1038/ncb1104-1054. - DOI - PubMed
1. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353–356. doi: 10.1126/science.1072994. - DOI - PubMed
1. Hardy J. New insights into the genetics of Alzheimer’s disease. Ann. Med. 1996;28(3):255–258. doi: 10.3109/07853899609033127. - DOI - PubMed
1. Campion D., Dumanchin C., Hannequin D., Dubois B., Belliard S., Puel M., Thomas-Anterion C., Michon A., Martin C., Charbonnier F., Raux G., Camuzat A., Penet C., Mesnage V., Martinez M., Clerget-Darpoux F., Brice A., Frebourg T. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am. J. Hum. Genet. 1999;65(3):664–670. doi: 10.1086/302553. - DOI - PMC - PubMed

Impact of the Cannabinoid System in Alzheimer's Disease - PubMed